Professor | Yanping Xu | Asia Growth Partners

Name	Yanping Xu
Contact Information	yanpingxu@tongji.edu.cn
Language ability	Chinese, English
Province	Shanghai

Name

Yanping Xu

Contact Information

yanpingxu@tongji.edu.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	Tongji University
Faculty	Life Sciences
Academic Background & Achievements	2010 - Bachelor's Degree: Xiamen University, School of Life Sciences 2015 - PhD: Fudan University, Biochemistry and Molecular Biology Selected for Shanghai Overseas High-Level Talents, Oriental Scholar Special Professor, Pujiang Talent Plan Received support from National Natural Science Foundation, National Key R&D Program, Shanghai Municipal Projects
Work Experience	2015-2020 - University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Postdoctoral Researcher 2020-Present - Tongji University, School of Life Science and Technology, Distinguished Research Fellow

University/Lab Affiliation and Title

Tongji University

Faculty

Life Sciences

Academic Background & Achievements

2010 - Bachelor's Degree: Xiamen University, School of Life Sciences
2015 - PhD: Fudan University, Biochemistry and Molecular Biology
Selected for Shanghai Overseas High-Level Talents, Oriental Scholar Special Professor, Pujiang Talent Plan
Received support from National Natural Science Foundation, National Key R&D Program, Shanghai Municipal Projects

Work Experience

2015-2020 - University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Postdoctoral Researcher
2020-Present - Tongji University, School of Life Science and Technology, Distinguished Research Fellow

Areas of Focus	Tumor Metabolism Tumor Immunology Epigenetics
Publications	Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma, Lin, M., He, J., Zhang, X., Sun, X., Dong, W., Zhang, R., Xu, Y., and Lv, L., 2023 TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential, He, J., Lin, M., Zhang, X., Zhang, R., Tian, T., Zhou, Y., Dong, W., Yang, Y., Sun, X., Dai, Y., Xu, Y., Zhang, Z., Xu, M., Lei, Q.Y., Xu, Y., and Lv, L., 2023 D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1, Zhang, R., Yang, Y., Dong, W., Lin, M., He, J., Zhang, X., Tian, T., Yang, Y., Chen, K., Lei, Q.Y., Zhang, S., Xu, Y., and Lv, L., 2022 TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling, Zhang, X., Li, S., He, J., Jin, Y., Zhang, R., Dong, W., Lin, M., Yang, Y., Tian, T., Zhou, Y., Xu, Y., Lei, Q.Y., Zhang, J., Zhang, Q., Xu, Y., and Lv, L., 2022 USP15 suppresses tumor immunity via deubiquitylation and inactivation of TET2, Chen, L.L., Smith, M.D., Lv, L., Nakagawa, T., Li, Z., Sun, S.C., Brown, N.G., Xiong, Y., and Xu, Y., 2020 Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy, Xu, Y., Lv, L., Liu, Y., Smith, M.D., Li, W.C., Tan, X.M., Cheng, M., Li, Z., Bovino, M., Aube, J., Xiong, Y., 2019 Vpr Targets TET2 for Degradation by CRL4(VprBP) E3 Ligase to Sustain IL-6 Expression and Enhance HIV-1 Replication, Lv, L., Wang, Q., Xu, Y., Tsao, L.C., Nakagawa, T., Guo, H., Su, L., and Xiong, Y., 2018 Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication, Murphy, C.M., Xu, Y., Li, F., Nio, K., Reszka-Blanco, N., Li, X., Wu, Y., Yu, Y., Xiong, Y., and Su, L., 2016 Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase, Xu, Y., Li, F., Lv, L., Li, T., Zhou, X., Deng, C.X., Guan, K.L., Lei, Q.Y., and Xiong, Y., 2014 Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization, Lv, L., Xu, Y., Zhao, D., Li, F.L., Wang, W., Sasaki, N., Jiang, Y., Zhou, X., Li, T.T., Guan, K.L., Lei, Q.Y., and Xiong, Y., 2013

Areas of Focus

Tumor Metabolism
Tumor Immunology
Epigenetics

Publications

Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma, Lin, M., He, J., Zhang, X., Sun, X., Dong, W., Zhang, R., Xu, Y.*, and Lv, L.*, 2023
TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential, He, J., Lin, M., Zhang, X., Zhang, R., Tian, T., Zhou, Y., Dong, W., Yang, Y., Sun, X., Dai, Y., Xu, Y., Zhang, Z., Xu, M., Lei, Q.Y., Xu, Y.*, and Lv, L.*, 2023
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1, Zhang, R., Yang, Y., Dong, W., Lin, M., He, J., Zhang, X., Tian, T., Yang, Y., Chen, K., Lei, Q.Y., Zhang, S.*, Xu, Y.*, and Lv, L.*, 2022
TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling, Zhang, X., Li, S., He, J., Jin, Y., Zhang, R., Dong, W., Lin, M., Yang, Y., Tian, T., Zhou, Y., Xu, Y., Lei, Q.Y., Zhang, J., Zhang, Q., Xu, Y.*, and Lv, L.*, 2022
USP15 suppresses tumor immunity via deubiquitylation and inactivation of TET2, Chen, L.L., Smith, M.D., Lv, L., Nakagawa, T., Li, Z., Sun, S.C., Brown, N.G., Xiong, Y.*, and Xu, Y.*, 2020
Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy, Xu, Y., Lv, L., Liu, Y., Smith, M.D., Li, W.C., Tan, X.M., Cheng, M., Li, Z., Bovino, M., Aube, J., Xiong, Y.*, 2019
Vpr Targets TET2 for Degradation by CRL4(VprBP) E3 Ligase to Sustain IL-6 Expression and Enhance HIV-1 Replication, Lv, L., Wang, Q., Xu, Y., Tsao, L.C., Nakagawa, T., Guo, H., Su, L.*, and Xiong, Y.*, 2018
Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication, Murphy, C.M., Xu, Y., Li, F., Nio, K., Reszka-Blanco, N., Li, X., Wu, Y., Yu, Y., Xiong, Y.*, and Su, L.*, 2016
Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase, Xu, Y., Li, F., Lv, L., Li, T., Zhou, X., Deng, C.X., Guan, K.L., Lei, Q.Y.*, and Xiong, Y.*, 2014
Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization, Lv, L., Xu, Y., Zhao, D., Li, F.L., Wang, W., Sasaki, N., Jiang, Y., Zhou, X., Li, T.T., Guan, K.L., Lei, Q.Y.*, and Xiong, Y.*, 2013

Metabolism Immunology Epigenetics Protein Modification Ubiquitination Deubiquitinases Immune Regulation Cancer Therapy Molecular Targets Gene Expression

Zhang Mengjie - Tongji University

Fang Wei - Shanghai Jiao Tong University

Weiqiang Lu - East China Normal University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us